{"ticker": {"uuid": "a89cf919-2315-4ea6-865b-fc38f91be27a", "symbol": "688192", "name": "Dizal (Jiangsu) Pharmaceutical Co., Ltd.", "exchange": "SHH", "country": "CN", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Asia deal flurry draws AZ, Spero to $1B+ Dizal, Innovent assets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPNkhiOUxfY2JzMUViYU9mRWwxSEVoaTY4QVg1TVRfWHdXejBxRngxalZuakRPZVE4aC1RUEphZWNFYlh0N2lhM2U5Y1dDU2hMeGJIQVRmQ2VCRjJiRmlvelNTU1BMSEc0Z183YVFNazU1ZHJBZERwdmRtVnlRLVp1VWYwVUdZVkxURE01SzdrVVpPOFlGcXlSTGVLLXNuLXp6emc?oc=5", "source_name": "BioWorld News", "published_at": "2026-07-14T16:00:00+00:00", "published_display": "14 Jul 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "About Dizal Pharmaceutical Co Ltd (688192.SS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE43OGlvTURUeVlCbmhodUgtNzZaajRrTEM4eDNuNjJwOFAya3c4YlNhN2JuLU81OUJnckp4RW1KWHh6b0tUTHhUc05LOF9wNmlMNkU3RDA1cjNxbWE2dmE3cXpBTU9Na1RtQ0ZHWQ?oc=5", "source_name": "Reuters", "published_at": "2026-07-14T13:57:33+00:00", "published_display": "14 Jul 2026 13:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Dizal Pharmaceutical Co Ltd. Class A Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE8yTnJRbWpsdHB0VmFuUm51M0Z1dzNZbE82akl5a0JQaTRibURIcDNkUXFDczhsUGZFWXNTaUc2ZloxY19HOW5yaTU4WXM4TW9Ya0txM2t0dTlHUUtDdUFzV0Z3?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T04:47:31+00:00", "published_display": "05 Jul 2026 04:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Dizal (Jiangsu) Pharmaceutical Co. Ltd. Class A \u2013 SSE:688192", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQMVE1QVJNMnlibzQxRmU1R3NhY0MxZlF2UEUtSGFZM0x0VmhaLW9nR2U0OXoxcFZlNl9KZHVBSk42eTdkRWoxMDkyb3l6ZDRCUFlaZDZZRWpyNkRFcm1BUWJnazYzOXp4UWI5Q2Ntcm00aWJzSjlGU1ozRVlTNHVTeldsZmRPMkd0VHJfMDVvSlhLSGhDU1U5aHF6RlhUQ3ZSNXpzak5RRG51QQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T11:05:50+00:00", "published_display": "26 Jun 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Asia deal flurry draws AZ, Spero to $1B+ Dizal, Innovent assets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPNkhiOUxfY2JzMUViYU9mRWwxSEVoaTY4QVg1TVRfWHdXejBxRngxalZuakRPZVE4aC1RUEphZWNFYlh0N2lhM2U5Y1dDU2hMeGJIQVRmQ2VCRjJiRmlvelNTU1BMSEc0Z183YVFNazU1ZHJBZERwdmRtVnlRLVp1VWYwVUdZVkxURE01SzdrVVpPOFlGcXlSTGVLLXNuLXp6emc?oc=5", "source_name": "BioWorld News", "published_at": "2026-07-14T16:00:00+00:00", "published_display": "14 Jul 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "About Dizal Pharmaceutical Co Ltd (688192.SS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE43OGlvTURUeVlCbmhodUgtNzZaajRrTEM4eDNuNjJwOFAya3c4YlNhN2JuLU81OUJnckp4RW1KWHh6b0tUTHhUc05LOF9wNmlMNkU3RDA1cjNxbWE2dmE3cXpBTU9Na1RtQ0ZHWQ?oc=5", "source_name": "Reuters", "published_at": "2026-07-14T13:57:33+00:00", "published_display": "14 Jul 2026 13:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Dizal Pharmaceutical Co Ltd. Class A Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE8yTnJRbWpsdHB0VmFuUm51M0Z1dzNZbE82akl5a0JQaTRibURIcDNkUXFDczhsUGZFWXNTaUc2ZloxY19HOW5yaTU4WXM4TW9Ya0txM2t0dTlHUUtDdUFzV0Z3?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T04:47:31+00:00", "published_display": "05 Jul 2026 04:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Dizal (Jiangsu) Pharmaceutical Co. Ltd. Class A \u2013 SSE:688192", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQMVE1QVJNMnlibzQxRmU1R3NhY0MxZlF2UEUtSGFZM0x0VmhaLW9nR2U0OXoxcFZlNl9KZHVBSk42eTdkRWoxMDkyb3l6ZDRCUFlaZDZZRWpyNkRFcm1BUWJnazYzOXp4UWI5Q2Ntcm00aWJzSjlGU1ozRVlTNHVTeldsZmRPMkd0VHJfMDVvSlhLSGhDU1U5aHF6RlhUQ3ZSNXpzak5RRG51QQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T11:05:50+00:00", "published_display": "26 Jun 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 46, "total_relevant": 4, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 4, "score": 50, "total": 4, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 72, "events": [{"event": "general", "label": "Market update", "weight": 2.0, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 61.42, "latest_week": "2026-07-17", "one_week_move": 31.4, "four_week_move": 61.8, "twelve_week_move": 10.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.058243, "market_dynamics_buy_signal": false, "relative_strength": 6.202878, "fair_value_gap": 25.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 41.5069, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+31.4% over one week, +61.8% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 55, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 2}, {"label": "BioWorld News", "count": 1}, {"label": "Reuters", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 4}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "4", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+31.4% over one week, +61.8% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Asia deal flurry draws AZ, Spero to $1B+ Dizal, Innovent assets"}], "updated_at": "2026-07-21T15:55:14.461673+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}